240 related articles for article (PubMed ID: 18682937)
1. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage.
Busk M; Horsman MR; Jakobsen S; Bussink J; van der Kogel A; Overgaard J
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2294-303. PubMed ID: 18682937
[TBL] [Abstract][Full Text] [Related]
2. Correlation analysis of [
Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
Acta Oncol; 2017 Sep; 56(9):1181-1188. PubMed ID: 28537761
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
[TBL] [Abstract][Full Text] [Related]
4. In vitro hypoxia responsiveness of [
Busk M; Horsman MR; Overgaard J; Jakobsen S
EJNMMI Radiopharm Chem; 2020 Jun; 5(1):14. PubMed ID: 32542416
[TBL] [Abstract][Full Text] [Related]
5. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET.
Busk M; Munk OL; Jakobsen S; Wang T; Skals M; Steiniche T; Horsman MR; Overgaard J
Acta Oncol; 2010 Oct; 49(7):922-33. PubMed ID: 20831479
[TBL] [Abstract][Full Text] [Related]
6. Concomitant [
Kepes Z; Hegedus E; Sass T; Csikos C; Szabo JP; Szugyiczki V; Hajdu I; Kertesz I; Opposits G; Imrek J; Balkay L; Kalman FK; Trencsenyi G
In Vivo; 2024; 38(2):574-586. PubMed ID: 38418132
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
8. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia.
Busk M; Horsman MR; Kristjansen PE; van der Kogel AJ; Bussink J; Overgaard J
Int J Cancer; 2008 Jun; 122(12):2726-34. PubMed ID: 18351643
[TBL] [Abstract][Full Text] [Related]
9. [
Nakajo M; Jinguji M; Tani A; Kajiya Y; Nandate T; Kitazano I; Yoshiura T
Mol Imaging Biol; 2020 Dec; 22(6):1609-1620. PubMed ID: 32651718
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
12. The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: a pilot study.
Zhang G; Li J; Wang X; Ma Y; Yin X; Wang F; Zheng H; Duan X; Postel GC; Li XF
J Nucl Med; 2015 Apr; 56(4):607-12. PubMed ID: 25722447
[TBL] [Abstract][Full Text] [Related]
13. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.
Christian N; Deheneffe S; Bol A; De Bast M; Labar D; Lee JA; Grégoire V
Radiother Oncol; 2010 Nov; 97(2):183-8. PubMed ID: 20304513
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
15. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.
Busk M; Mortensen LS; Nordsmark M; Overgaard J; Jakobsen S; Hansen KV; Theil J; Kallehauge JF; D'Andrea FP; Steiniche T; Horsman MR
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):186-97. PubMed ID: 23076620
[TBL] [Abstract][Full Text] [Related]
16. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?
Busk M; Horsman MR; Jakobsen S; Hansen KV; Bussink J; van der Kogel A; Overgaard J
Radiother Oncol; 2009 Sep; 92(3):429-36. PubMed ID: 19729214
[TBL] [Abstract][Full Text] [Related]
17. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes.
Busk M; Horsman MR; Overgaard J; Jakobsen S
Acta Oncol; 2019 Oct; 58(10):1476-1482. PubMed ID: 31432722
[No Abstract] [Full Text] [Related]
19. Evolution of [
Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
Acta Oncol; 2017 Apr; 56(4):516-524. PubMed ID: 28358668
[TBL] [Abstract][Full Text] [Related]
20. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
